Semaglutide (marketed as Ozempic or Wegovy) and Tirzepatide (Mounjaro or Zepbound) are advanced medications designed for weight loss and metabolic health. Both are GLP-1 receptor agonists that work by mimicking natural hormones in the body to regulate appetite and improve blood sugar control. Semaglutide focuses on appetite suppression and fat loss, while Tirzepatide adds dual-action benefits by also enhancing insulin sensitivity. These treatments are administered through weekly injections and are most effective when paired with lifestyle adjustments such as healthy eating and exercise.
Semaglutide is an FDA-approved medication for weight management and the treatment of type 2 diabetes. It helps control appetite and improve blood sugar levels by mimicking a natural hormone that regulates these functions in the body. By supporting gradual and sustainable weight loss and improving glycemic control, Semaglutide promotes both a healthier lifestyle and better metabolic health.
Tirzepatide is a breakthrough treatment for weight loss and type 2 diabetes management. This injectable medication works by targeting multiple hormones to reduce appetite, improve blood sugar control, and promote significant weight loss.